Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005636 · ClinicalTrials.gov registry record · Phase 3

Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery

A Phase 3 study of Malignant Mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 3
Development phase
3
Study locations

NCT00005636: Completed Phase 3 study of Malignant Mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00005636 is a Phase 3 study of Malignant Mesothelioma that has completed, run by Memorial Sloan Kettering Cancer Center. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005636, a Phase 3 study of Malignant Mesothelioma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 3
Development phase
3
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that cannot be removed by surgery.

Conditions Studied

Interventions

  • DRUG cisplatin
  • DRUG pemetrexed disodium

Study Locations (3)

New Jersey

  • Cancer Institute of New Jersey - New Brunswick

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Ohio

  • Ireland Cancer Center - Cleveland

Trial Details

FieldValue
Start Date 1999-11
Est. Completion 2000-11
Phase Phase 3

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT00005636

The ClinicalTrials.gov registry entry for NCT00005636 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which cisplatin is the first listed.

NCT00005636 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New Jersey, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT00005636 about?

NCT00005636 is a clinical study titled "Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura. PURPOSE: Randomized phase III trial to compare the...

What is the current status of trial NCT00005636?

This trial is currently completed. It is a Phase 3 study. The study started on 1999-11. Estimated completion is 2000-11.

What conditions does trial NCT00005636 study?

This clinical trial studies the following conditions: Malignant Mesothelioma.

What interventions are being tested in trial NCT00005636?

The interventions under investigation include: cisplatin (DRUG), pemetrexed disodium (DRUG).

Who is sponsoring clinical trial NCT00005636?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005636 being conducted?

This trial has 3 study locations across New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.